Skip to main content
SpringerLink
Log in

Systemtherapie bei Endometriumkarzinom

Systemic therapy for endometrial cancer

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Hintergrund

Die Entscheidung über eine adjuvante Systemtherapie beim Endometriumkarzinom erfolgt anhand von klinisch-pathologischen Risikofaktoren.

Material und Methoden

Es erfogten eine selektive Literaturrecherche sowie eine Auswertung der aktuellen Leitlinienempfehlungen.

Ergebnisse und Schlussfolgerung

In der Niedrigrisikosituation ist keine adjuvante Therapie nach Operation und im mittleren Risiko die adjuvante Strahlentherapie nach Operation indiziert. In der Hochrisikosituation wie bei fortgeschrittenen Karzinomen sollte eine systemische Chemotherapie mit Carboplatin-Paclitaxel erfolgen. In der palliativen Situation kann eine gestagenbasierte Therapie erwogen werden. Aufgrund der häufigen Komorbiditäten sollten Nutzen und Risiko sorgfältig im Einzelfall abgewogen werden.

Abstract

Background

The decision on adjuvant systemic therapy for endometrial cancer is based on the clinicopathological risk factors.

Material and methods

A selective literature review and analysis of the current guideline recommendations were carried out.

Results and conclusion

In the low-risk situation no adjuvant treatment is necessary after surgery but in medium risk patients adjuvant radiotherapy is indicated after surgery. In the high-risk situation, such as advanced carcinoma systemic chemotherapy with carboplatin-paclitaxel should be carried out. In palliative care situations a gestagen-based therapy should be considered. Due to frequent comorbidities, the risks and benefits should be carefully considered in each individual case.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Colombo N, Creutzberg C, Amant F et al (2016) ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol 27:16–41

    Article  CAS  PubMed  Google Scholar 

  2. Martin-Hirsch PP, Bryant A, Keep SL et al (2011) Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.cd001040.pub2

    Google Scholar 

  3. Johnson N, Bryant A, Miles T et al (2011) Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev. doi:10.1002/14651858.cd003175.pub2

    Google Scholar 

  4. Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 24:36–44

    Article  CAS  PubMed  Google Scholar 

  5. Secord AA, Geller MA, Broadwater G et al (2013) A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 128:65–70

    Article  CAS  PubMed  Google Scholar 

  6. Lee LJ, Viswanathan AN (2012) Combined chemotherapy and radiation improves survival for node-positive endometrial cancer. Gynecol Oncol 127:32–37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mundt AJ, McBride R, Rotmensch J et al (2001) Significant pelvic recurrence in high-risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50:1145–1153

    Article  CAS  PubMed  Google Scholar 

  8. Hasegawa K, Nagao S, Yasuda M et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer 24:S90–S95

    Article  PubMed  Google Scholar 

  9. Sagae S, Susumu N, Viswanathan AN et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma. Int J Gynecol Cancer 24:S83–S89

    Article  PubMed  Google Scholar 

  10. Thigpen JT, Brady MF, Alvarez RD et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736–1744

    CAS  PubMed  Google Scholar 

  11. Decruze SB, Green JA (2007) Hormone therapy in advanced and recurrent endometrial cancer: A systematic review. Int J Gynecol Cancer 17:964–978

    Article  CAS  PubMed  Google Scholar 

  12. Lentz SS, Brady MF, Major FJ et al (1996) High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 14:357–361

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität zu Köln, Kerpener Straße 62, 50924, Köln, Deutschland

    M. R. Mallmann &  P. Mallmann

Authors
  1. M. R. Mallmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Mallmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Mallmann.

Ethics declarations

Interessenkonflikt

M.R. Mallmann und P. Mallmann geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mallmann, M.R., Mallmann, P. Systemtherapie bei Endometriumkarzinom. Onkologe 23, 34–36 (2017). https://doi.org/10.1007/s00761-016-0129-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-016-0129-y

Schlüsselwörter

Keywords

Search

Navigation